Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ORIC Pharmaceuticals Inc
ORIC | US
13.85
USD0.34
2.52%
ORIC | US
About ORIC Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
05/03/2026
Close
13.85
Open
13.22
High
13.86
Low
13.05
ORIC Pharmaceuticals Inc. a clinical-stage biopharmaceutical company discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533 an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944 an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114 a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco California.
View LessORIC | US
Risk
71.2
Sharpe
0.94
Luna's Score
52/100
Recommendation
Hold
Luna says (ORIC | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
76.2%1 month
71.2%3 months
73.0%6 months
70.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.13
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
0.13
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-124.06M
MarketCap
977.01M
MarketCap(USD)
977.01M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-38.79
Short ratio
23.39
Short perc.
17.65
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
3.72
Range1M
4.55
Range3M
6.42
Volumes: Market Activity
Rel. volume
1.12
Price X volume
23.15M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.13 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.13 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 72.96 | 72.80 | Par |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 977.01M | 3.66B | Emerging |
